Drugs / NV-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06051760 | Dec 2023 → Mar 2025 overdue | cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NV-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06051760 ↗ |
| Modality | Vaccine | “NV-001 is a type of tumor vaccine generated by hybridization of the tumor cell membrane and adjuvant membrane to stimulate the immune reactions against cancer cells.” NCT06051760 ↗ |